Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Karyopharm Therapeutics
KPTI
Karyopharm Therapeutics
Liquidity Strains And Overreliance Will Mar Outlook But Support Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
15 Aug 25
Updated
15 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$8.00
21.3% undervalued
intrinsic discount
15 Aug
US$6.30
Loading
1Y
-49.6%
7D
6.4%
Author's Valuation
US$8.0
21.3% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$8.0
21.3% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-216m
251m
2014
2017
2020
2023
2025
2026
2028
Revenue US$240.9m
Earnings US$38.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
26.90%
Biotech revenue growth rate
11.77%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.32%
Calculation
US$38.41m
Earnings '28
x
2.91x
PE Ratio '28
=
US$111.61m
Market Cap '28
US$111.61m
Market Cap '28
/
9.84m
No. shares '28
=
US$11.34
Share Price '28
US$11.34
Share Price '28
Discounted to 2025 @ 12.32% p.a.
=
US$8.00
Fair Value '25
